CMBL Protein (His Tag)

Carboxymethylenebutenolidase homolog (Pseudomonas) Protein Datasheet

CMBL Protein Product Information

• Synonym: FLJ23617
• Protein Construction: A DNA sequence encoding the human CMBL (Q96DG6) (Met 1-Met 245) was expressed, with a N-terminal polyhistidine tag.
• Source: Human
• Expression Host: E. Coli

CMBL Protein QC Testing

• Purity: > 97 % as determined by SDS-PAGE.
• Endotoxin: Please contact us for more information.
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Met
• Molecular Mass: The recombinant human CMBL comprises 260 amino acids and has a calculated molecular mass of 30 KDa. It migrates as an approximately 28 KDa band in SDS-PAGE under reducing conditions.
• Formulation: Lyophilized from sterile 20mM Tris, 0.1% Brij35, pH 8.0
  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.
• SDS-PAGE: CMBL protein

CMBL Protein Usage Guide

• Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

CMBL Protein Description

Carboxymethylenebutenolidase(CMBL) is a hydrolase specially acting on carboxylic ester bonds. Human CMBL is a human homolog of Pseudomonas dienelactone hydrolase involved in the bacterial halocatechol degradation pathway. The ubiquitous expression of human CMBL gene transcript in various tissues was observed. CMBL was demonstrated to be the primary olmesartan medoxomil(OM) bioactivating enzyme in the liver and intestine. The recombinant human CMBL expressed in mammalian cells was clearly shown to activate OM. The recombinant CMBL also converted other prodrugs having the same ester structure as OM, faropenem medoxomil and lenampicillin, to their active metabolites. CMBL exhibited a unique sensitivity to chemical inhibitors, thus, being distinguishable from other known esterases.

References

1. Ishizuka T, et al. (2010) The Journal of Biological Chemistry. 285: 11892-902.
2. Schmidt E, et al.(1980) Biochem J. 192 (1): 339–47.